TrialCell reports. Medicine2025

Neoadjuvant anlotinib/sintilimab plus chemotherapy in triple-negative breast cancer (NeoSACT): Phase 2 trial.

Liulu Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.